Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a chinese population

Therapeutic Drug Monitoring

Volumn 36, Issue 5, 2014, Pages 612-617

  Wang, Xin Chen ^a   Xu, Du Juan ^a   Chen, Gui Hai ^a   Xia, Quan ^a   Liu, Li Na ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

clinical medication individualization; depression; neurotrophic factor; paroxetine; polymorphisms

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CHINESE; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DSM-IV; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAMILTON DEPRESSION RATING SCALE; HAPLOTYPE MAP; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DEPRESSIVE DISORDER, MAJOR; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOTYPE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MALE; MIDDLE AGED; PAROXETINE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN UPTAKE INHIBITORS;

EID: 84930180964     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000062     Document Type: Article

References (29)

1. Kumar P, Waiter G, Ahearn T, et al. Abnormal temporal difference rewardlearning signals in major depression. Brain. 2008;131:2084-2093.
2. Oral E, Canpolat S, Yildirim S, et al. Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder. Brain Res Bull. 2012;88:454-459.
3. Hibi Y, Nitta A, Nabeshima T, et al. Possible relation of BDNF and GDNF to neuropsychiatric disorders. Nihon Shinekei Yakuriqaku Zasshi. 2009;29:85-89.
4. LaFrance WC Jr, Leaver K, Stopa EG, et al. Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures. Neurology. 2010;75:1285-1291.
5. Tseng PT, Lee Y, Lin PY. Age-associated decrease in serum glial cell linederived neurotrophic factor levels in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:334-339.
6. Fava M, Davidson KG. Definition and epidemiology of treatmentresistant depression. Psychiatr Clin North Am. 1996;2:179-200.
7. Angelucci F, Croce N, Spalletta G, et al. Paroxetine rapidly modulated the expression of brain-derived neurotrophic factor mRNA and protein in a human glioblastoma-astrocytoma cell line. Pharmacology. 2011;87:5-10.
8. Golan M, Schreiber G, Avissar S. Antidepressants elevate GDNF expression and release from C6 glioma cells in a b-arrestin1-dependent, CREB interactive pathway. Int J Neuropsychopharmacol. 2011;14:1289-1300.
9. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15:97-98.
10. Lin KM, Tsou HH, Tsai IJ, et al. CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics. 2010;11:1535-1543.
11. Josse AR, Da Costa LA, Campos H, et al. Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption. Am J Clin Nutr. 2012;96:665-671.
12. Rodenburg EM, Eijgelsheim M, Geleijnse JM, et al. CYP1A2 and coffee intake and the modifying effect of sex, age, and smoking. Am J Clin Nutr. 2012;96:182-187.
13. Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 2008;30:474-482.
14. Ververs FF, Voorbij HA, Zwarts P, et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet. 2009;48:677-683.
15. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008;11:1169-1180.
16. Molteni R, Calabrese F, Chourbaji S, et al. Depression-prone mice with reduced glucocorticoid receptor expression display an altered stressdependent regulation of brain-derived neurotrophic factor and activityregulated cytoskeleton-associated protein. J Psychopharmacol. 2010;24: 595-603.
17. Bayer TA, Schramm M, Feldmann N, et al. Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:881-888.
18. Russo-Neustadt A, Ha T, Ramirez R, et al. Physical activityantidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. Behav Brain Res. 2001; 120:87-95.
19. Saarelainen T, Hendolin P, Lucas G, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci. 2003;23:349-357.
20. Choi MJ, Kang RH, Lim SW, et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 2006;1118:176-182.
21. Zhang L, Fang Y, Zeng Z, et al. BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response. J Alzheimers Dis. 2011;26:523-530.
22. Kocabas NA, Antonijevic I, Faghel C, et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol. 2011;26:1-10.
23. Fukumoto N, Fujii T, Combarros O, et al. Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer's disease: new data and meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:235-242.
24. Keers R, Aitchison KJ. Gender differences in antidepressant drug response. Int Rev Psychiatry. 2010;22:485-500.
25. Yoshimura R, Kishi T, Suzuki A, et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1022-1025.
26. Yoshimura R, Kishi T, Hori H, et al. No association between the response to the addition of an atypical antipsychotic drug to an SSRI or SNRI and the BDNF (Val66Met) polymorphism in refractory major depressive disorder in Japanese patients. Clin Psychopharmacol Neurosci. 2012;10:49-53.
27. Takebayashi M, Hisaoka K, Nishida A, et al. Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int J Neuropsychopharmacol. 2006;9: 607-612.
28. Otsuki K, Uchida S, Watanuki T, et al. Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res. 2008;42:1145-1153.
29. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.